These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 24341617)

  • 1. Busulfan and melphalan as consolidation therapy with autologous peripheral blood stem cell transplantation following Children's Oncology Group (COG) induction platform for high-risk neuroblastoma: early results from a single institution.
    Soni S; Pai V; Gross TG; Ranalli M
    Pediatr Transplant; 2014 Mar; 18(2):217-20. PubMed ID: 24341617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toxicities of busulfan/melphalan versus carboplatin/etoposide/melphalan for high-dose chemotherapy with stem cell rescue for high-risk neuroblastoma.
    Desai AV; Heneghan MB; Li Y; Bunin NJ; Grupp SA; Bagatell R; Seif AE
    Bone Marrow Transplant; 2016 Sep; 51(9):1204-10. PubMed ID: 27159174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of toxicity following different conditioning regimens (busulfan/melphalan and carboplatin/etoposide/melphalan) for advanced stage neuroblastoma: Experience of two transplant centers.
    Elborai Y; Hafez H; Moussa EA; Hammad M; Hussein H; Lehmann L; Elhaddad A
    Pediatr Transplant; 2016 Mar; 20(2):284-9. PubMed ID: 26614402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 131I-MIBG followed by consolidation with busulfan, melphalan and autologous stem cell transplantation for refractory neuroblastoma.
    French S; DuBois SG; Horn B; Granger M; Hawkins R; Pass A; Plummer E; Matthay K
    Pediatr Blood Cancer; 2013 May; 60(5):879-84. PubMed ID: 23024113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose busulfan and melphalan as conditioning regimen for autologous peripheral blood progenitor cell transplantation in high-risk neuroblastoma patients.
    Molina B; Alonso L; Gonzalez-Vicent M; Andion M; Hernandez C; Lassaletta A; Cormenzana M; Lopez-Ibor B; Villa M; Molina J; Diaz MA
    Pediatr Hematol Oncol; 2011 Mar; 28(2):115-23. PubMed ID: 21299340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term results of the combination of the N7 induction chemotherapy and the busulfan-melphalan high dose chemotherapy.
    Valteau-Couanet D; Le Deley MC; Bergeron C; Ducassou S; Michon J; Rubie H; Le Teuff G; Coze C; Plantaz D; Sirvent N; Bouzy J; Chastagner P; Hartmann O
    Pediatr Blood Cancer; 2014 Jun; 61(6):977-81. PubMed ID: 23970413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Busulfan-melphalan in high-risk neuroblastoma: the 30-year experience of a single institution.
    Proust-Houdemont S; Pasqualini C; Blanchard P; Dufour C; Benhamou E; Goma G; Semeraro M; Raquin MA; Hartmann O; Valteau-Couanet D
    Bone Marrow Transplant; 2016 Aug; 51(8):1076-81. PubMed ID: 27042850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Veno-occlusive disease of the liver after high-dose cytoreductive therapy with busulfan and melphalan for autologous blood stem cell transplantation in multiple myeloma patients.
    Carreras E; Rosiñol L; Terol MJ; Alegre A; de Arriba F; García-Laraña J; Bello JL; García R; León A; Martínez R; Peñarrubia MJ; Poderós C; Ribas P; Ribera JM; San Miguel J; Bladé J; Lahuerta JJ;
    Biol Blood Marrow Transplant; 2007 Dec; 13(12):1448-54. PubMed ID: 18022574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous busulfan and melphalan as a conditioning regimen for autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: a matched comparison to a melphalan-only approach.
    Blanes M; Lahuerta JJ; González JD; Ribas P; Solano C; Alegre A; Bladé J; San Miguel JF; Sanz MA; de la Rubia J
    Biol Blood Marrow Transplant; 2013 Jan; 19(1):69-74. PubMed ID: 22897964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Consolidation of first-line therapy with busulphan and melphalan, and autologous stem cell rescue in children with Ewing's sarcoma.
    Drabko K; Raciborska A; Bilska K; Styczynski J; Ussowicz M; Choma M; Wojcik B; Zaucha-Prazmo A; Gorczynska E; Skoczen S; Wozniak W; Chybicka A; Wysocki M; Gozdzik J; Kowalczyk J
    Bone Marrow Transplant; 2012 Dec; 47(12):1530-4. PubMed ID: 22609883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myeloablative Busulfan/Melphalan Consolidation following Induction Chemotherapy for Patients with Newly Diagnosed High-Risk Neuroblastoma: Children's Oncology Group Trial ANBL12P1.
    Granger MM; Naranjo A; Bagatell R; DuBois SG; McCune JS; Tenney SC; Weiss BD; Mosse YP; Asgharzadeh S; Grupp SA; Hogarty MD; Gastier-Foster JM; Mills D; Shulkin BL; Parisi MT; London WB; Han-Chang J; Panoff J; von Allmen D; Jarzembowski JA; Park JR; Yanik GA
    Transplant Cell Ther; 2021 Jun; 27(6):490.e1-490.e8. PubMed ID: 33823167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose busulfan/melphalan as conditioning for autologous PBPC transplantation in pediatric patients with solid tumors.
    Diaz MA; Vicent MG; Madero L
    Bone Marrow Transplant; 1999 Dec; 24(11):1157-9. PubMed ID: 10642802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose chemotherapy for high-risk retinoblastoma: clinical course and outcome of 14 cases in the National Cancer Center, Japan.
    Yasui N; Kawamoto H; Fujiwara M; Aihara Y; Ogawa C; Hosono A; Suzuki S
    Bone Marrow Transplant; 2015 Feb; 50(2):221-4. PubMed ID: 25437249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thiotepa and melphalan based single, tandem, and triple high dose therapy and autologous stem cell transplantation for high risk neuroblastoma.
    Saarinen-Pihkala UM; Hovi L; Koivusalo A; Jahnukainen K; Karikoski R; Sariola H; Wikström S
    Pediatr Blood Cancer; 2012 Dec; 59(7):1190-7. PubMed ID: 22492714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resource Utilization and Toxicities After Carboplatin/Etoposide/Melphalan and Busulfan/Melphalan for Autologous Stem Cell Rescue in High-Risk Neuroblastoma Using a National Administrative Database.
    Desai AV; Seif AE; Li Y; Getz K; Fisher BT; Huang V; Mante A; Aplenc R; Bagatell R
    Pediatr Blood Cancer; 2016 May; 63(5):901-7. PubMed ID: 26797923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Consolidation Therapy for Newly Diagnosed Pediatric Patients with High-Risk Neuroblastoma Using Busulfan/Melphalan, Autologous Hematopoietic Cell Transplantation, Anti-GD2 Antibody, Granulocyte-Macrophage Colony-Stimulating Factor, Interleukin-2, and Haploidentical Natural Killer Cells.
    Talleur AC; Triplett BM; Federico S; Mamcarz E; Janssen W; Wu J; Shook D; Leung W; Furman WL
    Biol Blood Marrow Transplant; 2017 Nov; 23(11):1910-1917. PubMed ID: 28733263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose busulfan and melphalan as conditioning regimen for autologous peripheral blood progenitor cell transplantation in high-risk ewing sarcoma patients: a long-term follow-up single-center study.
    Diaz MA; Lassaletta A; Perez A; Sevilla J; Madero L; Gonzalez-Vicent M
    Pediatr Hematol Oncol; 2010 May; 27(4):272-82. PubMed ID: 20426518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors Impacting Time to Engraftment in Patients With High-risk Neuroblastoma Following Autologous Stem Cell Transplant.
    Hillier K; Cheng WS; Whittle SB; Krance R; Foster JH
    J Pediatr Hematol Oncol; 2020 Oct; 42(7):e569-e574. PubMed ID: 32032244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose chemotherapy with autologous stem-cell rescue in children and adults with newly diagnosed pineoblastomas.
    Gururangan S; McLaughlin C; Quinn J; Rich J; Reardon D; Halperin EC; Herndon J; Fuchs H; George T; Provenzale J; Watral M; McLendon RE; Friedman A; Friedman HS; Kurtzberg J; Vredenbergh J; Martin PL
    J Clin Oncol; 2003 Jun; 21(11):2187-91. PubMed ID: 12775745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tandem high-dose chemotherapy with thiotepa and busulfan-melphalan and autologous stem cell transplantation in very high-risk neuroblastoma patients.
    Pasqualini C; Dufour C; Goma G; Raquin MA; Lapierre V; Valteau-Couanet D
    Bone Marrow Transplant; 2016 Feb; 51(2):227-31. PubMed ID: 26524264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.